Global Alzheimer's Disease Therapeutics and Diagnostics Market By Type (Biomarkers, Cholinesterase inhibitors, NMDA receptor antagonists, Brain imaging, and Blood tests), By Application (Drugs Market, and Diagnostics Market), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019–2028
- Published date: Nov 2021
- Report ID: 21748
- Number of Pages: 381
- Format:
- keyboard_arrow_up
- 1. Alzheimer's Disease Therapeutics and Diagnostics Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Alzheimer's Disease Therapeutics and Diagnostics Market Overview
- 3.1. Alzheimer's Disease Therapeutics and Diagnostics Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Manufacturer Intensity Map
- 3.1. Alzheimer's Disease Therapeutics and Diagnostics Market Dynamics
- 4. Global Alzheimer's Disease Therapeutics and Diagnostics Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Alzheimer's Disease Therapeutics and Diagnostics Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. Biomarkers
- 4.4. Cholinesterase inhibitors
- 4.5. NMDA receptor antagonists
- 4.6. Brain imaging
- 4.7. Blood tests
- 5. Global Alzheimer's Disease Therapeutics and Diagnostics Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Alzheimer's Disease Therapeutics and Diagnostics Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. Drugs Market
- 5.4. Diagnostics Market
- 6. Global Alzheimer's Disease Therapeutics and Diagnostics Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.2. Europe
- 6.2.1. Europe Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Rest of Europe
- 6.2.1. Europe Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia
- 6.3.1. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Alzheimer's Disease Therapeutics and Diagnostics Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. Namenda
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. Aricept
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. Exelon
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. Solanezumab
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. Gantenerumab
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. Verubecestat
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Pfizer
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. Eisai
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. Actavis
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. Lundbeck
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 7.13. Daiichi Sankyo
- 7.13.1. Company Overview
- 7.13.2. Financial Highlights
- 7.13.3. Product Portfolio
- 7.13.4. SWOT Analysis
- 7.13.5. Key Strategies and Developments
- 7.14. Novartis
- 7.14.1. Company Overview
- 7.14.2. Financial Highlights
- 7.14.3. Product Portfolio
- 7.14.4. SWOT Analysis
- 7.14.5. Key Strategies and Developments
- 7.15. TauRx
- 7.15.1. Company Overview
- 7.15.2. Financial Highlights
- 7.15.3. Product Portfolio
- 7.15.4. SWOT Analysis
- 7.15.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- 1. Alzheimer's Disease Therapeutics and Diagnostics Market Introduction
- Namenda
- Aricept
- Exelon
- Solanezumab
- Gantenerumab
- Verubecestat
- Pfizer Inc Company Profile
- Eisai
- Actavis
- Lundbeck
- Daiichi Sankyo
- Novartis AG Company Profile
- TauRx
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |